Fresenius SE

Investor News 2004

08.12.2004Fresenius Kabi: Market leader builds on success
PDF Text as PDF-File
07.12.2004Fresenius Kabi strengthens position in central and eastern Europe
PDF Text as PDF-File
02.11.20041st-3rd Quarter 2004: Fresenius continues successful revenue and earnings development, raises earnings outlook
(for tables please see pdf-file)
PDF Text as PDF-File
29.10.2004Fresenius ProServe to focus on core activities Agreement reached on the sale of nursing care business
PDF Text as PDF-File
19.10.2004Fresenius announces changes to the Management Board
PDF Text as PDF-File
06.09.2004Fresenius Kabi is expanding its market presence in Australia
PDF Text as PDF-File
04.08.2004First Half 2004; Fresenius raises sales and earnings outlook
(for tables please see pdf-file)
PDF Text as PDF-File
06.05.2004First Quarter 2004: Excellent start into fiscal year 2004
(for tables please see pdf-file)
PDF Text as PDF-File
19.03.2004Fresenius receives Orphan Drug Designation for antibody removab® to treat patients with ovarian cancer
17.03.2004Fresenius AG appoints new Member of the Management Board
25.02.2004Full Year 2003
(for tables please see pdf-file)
PDF Text as PDF-File
15.01.2004Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies
Home  >  Investor Relations  >  News  >  Investor News  >  2004